摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-Ethoxy-2-methyl-1,3-thiazole-4-sulfonyl chloride | 89502-03-4

中文名称
——
中文别名
——
英文名称
5-Ethoxy-2-methyl-1,3-thiazole-4-sulfonyl chloride
英文别名
5-ethoxy-2-methyl-1,3-thiazole-4-sulfonyl chloride
5-Ethoxy-2-methyl-1,3-thiazole-4-sulfonyl chloride化学式
CAS
89502-03-4
化学式
C6H8ClNO3S2
mdl
——
分子量
241.7
InChiKey
LRUOTUHZPGOBAB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    13
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    92.9
  • 氢给体数:
    0
  • 氢受体数:
    5

文献信息

  • 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
    申请人:MERCK SHARP & DOHME CORP.
    公开号:US20160304505A1
    公开(公告)日:2016-10-20
    The invention provides certain benzoxazine compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R a , R b , R c , R d , R g , and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
  • CARBAMATE BENZOXAZINE PROPIONIC ACIDS AND ACID DERIVATIVES FOR MODULATION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
    申请人:MERCK SHARP & DOHME CORP.
    公开号:US20160311787A1
    公开(公告)日:2016-10-27
    The invention provides certain benzoxazine compounds of the Formula (I) or pharmaceutically acceptable salts thereof wherein R 1 , R 2 , R a1 , R a2 , R b1 , R b2 , R c , R d , and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
  • US9663502B2
    申请人:——
    公开号:US9663502B2
    公开(公告)日:2017-05-30
  • US9783511B2
    申请人:——
    公开号:US9783511B2
    公开(公告)日:2017-10-10
查看更多